FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034771449> ?p ?o ?g. }

• W2034771449 endingPage "488" @default.
• W2034771449 startingPage "481" @default.
• W2034771449 abstract "Purpose: The radiobiology of prostate cancer appears to favor large fractions. Accelerated hypofractionation treatments may therefore be used to improve the therapeutic ratio, particularly when the doses to rectum and bladder are kept below the prostate dose. The 5-year experience at William Beaumont Hospital (WBH) and the California Endocurietherapy Center (CET) with accelerated-hypofractionated high-dose-rate (HDR) monotherapy in favorable prostate cancer is presented. Materials and Methods: Between 1993 and 2004, 454 patients were treated with brachytherapy of which 248 treated with HDR and 206 patients treated with low-dose-rate Palladium (LDR-Pd103). The WBH-HDR dose was 38 Gy, in 4 fractions, twice a day. The CET-HDR dose was 42 Gy in 6 fractions in 2 separate implants 1 week apart. The WBH-LDR dose was 120 Gy. Results: Median follow-up was 4.8 years. The 5-year Phoenix biochemical control (BC) was 89%, 91%, and 88% for WBH-LDR, WBH- HDR, and CET-HDR, respectively. The majority of complications were grade 1. HDR was associated with less acute grade 1 to 3 dysuria 60% versus 39%, (P < 0.001), urinary frequency/urgency 90% to58% (P < 0.001), and rectal pain 17% to 6.5% (P < 0.001). Long-term urinary frequency/urgency 54% versus 43%, (P = 0.03) and dysuria 22% versus 15% were less with HDR. The 5-year actuarial impotence rate was 30% for LDR and 20% for HDR (P = 0.23). Conclusions: Although the same 5-year BC rates were achieved with HDR (248 patients) and LDR (206 patients) monotherapy, HDR brachytherapy was associated with less acute and chronic genitourinary and gastrointestinal toxicities. As another accepted standard of care, accelerated hypofractionated HDR monotherapy is target specific and efficient radiobiologically than EBRT which has many smaller doses per fraction. It could be considered today as the best option in accelerated hypofractionated prostate cancer treatment." @default.
• W2034771449 created "2016-06-24" @default.
• W2034771449 creator A5006101201 @default.
• W2034771449 creator A5006151030 @default.
• W2034771449 creator A5017438487 @default.
• W2034771449 creator A5029089922 @default.
• W2034771449 creator A5059255743 @default.
• W2034771449 creator A5089120429 @default.
• W2034771449 date "2010-10-01" @default.
• W2034771449 modified "2023-09-25" @default.
• W2034771449 title "High-Dose-Rate Prostate Brachytherapy" @default.
• W2034771449 cites W1997021025 @default.
• W2034771449 cites W2002847955 @default.
• W2034771449 cites W2016426829 @default.
• W2034771449 cites W2021499491 @default.
• W2034771449 cites W2031307716 @default.
• W2034771449 cites W2035529696 @default.
• W2034771449 cites W2035583253 @default.
• W2034771449 cites W2046548861 @default.
• W2034771449 cites W2050744051 @default.
• W2034771449 cites W2050792510 @default.
• W2034771449 cites W2054527786 @default.
• W2034771449 cites W2056643793 @default.
• W2034771449 cites W2071339389 @default.
• W2034771449 cites W2071750479 @default.
• W2034771449 cites W2089778115 @default.
• W2034771449 cites W2099288242 @default.
• W2034771449 cites W2118157857 @default.
• W2034771449 cites W2124537997 @default.
• W2034771449 cites W2129638731 @default.
• W2034771449 cites W2130514725 @default.
• W2034771449 cites W2138320929 @default.
• W2034771449 cites W2143381715 @default.
• W2034771449 cites W2153674426 @default.
• W2034771449 cites W2159598747 @default.
• W2034771449 cites W4234967990 @default.
• W2034771449 doi "https://doi.org/10.1097/coc.0b013e3181b9cd2f" @default.
• W2034771449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19952715" @default.
• W2034771449 hasPublicationYear "2010" @default.
• W2034771449 type Work @default.
• W2034771449 sameAs 2034771449 @default.
• W2034771449 citedByCount "143" @default.
• W2034771449 countsByYear W20347714492012 @default.
• W2034771449 countsByYear W20347714492013 @default.
• W2034771449 countsByYear W20347714492014 @default.
• W2034771449 countsByYear W20347714492015 @default.
• W2034771449 countsByYear W20347714492016 @default.
• W2034771449 countsByYear W20347714492017 @default.
• W2034771449 countsByYear W20347714492018 @default.
• W2034771449 countsByYear W20347714492019 @default.
• W2034771449 countsByYear W20347714492020 @default.
• W2034771449 countsByYear W20347714492021 @default.
• W2034771449 countsByYear W20347714492022 @default.
• W2034771449 crossrefType "journal-article" @default.
• W2034771449 hasAuthorship W2034771449A5006101201 @default.
• W2034771449 hasAuthorship W2034771449A5006151030 @default.
• W2034771449 hasAuthorship W2034771449A5017438487 @default.
• W2034771449 hasAuthorship W2034771449A5029089922 @default.
• W2034771449 hasAuthorship W2034771449A5059255743 @default.
• W2034771449 hasAuthorship W2034771449A5089120429 @default.
• W2034771449 hasConcept C121608353 @default.
• W2034771449 hasConcept C126322002 @default.
• W2034771449 hasConcept C126894567 @default.
• W2034771449 hasConcept C141071460 @default.
• W2034771449 hasConcept C19527891 @default.
• W2034771449 hasConcept C2776235491 @default.
• W2034771449 hasConcept C2776845205 @default.
• W2034771449 hasConcept C2777416452 @default.
• W2034771449 hasConcept C2778648096 @default.
• W2034771449 hasConcept C2780192828 @default.
• W2034771449 hasConcept C2781074409 @default.
• W2034771449 hasConcept C2989005 @default.
• W2034771449 hasConcept C3017588741 @default.
• W2034771449 hasConcept C509974204 @default.
• W2034771449 hasConcept C71924100 @default.
• W2034771449 hasConcept C77411442 @default.
• W2034771449 hasConceptScore W2034771449C121608353 @default.
• W2034771449 hasConceptScore W2034771449C126322002 @default.
• W2034771449 hasConceptScore W2034771449C126894567 @default.
• W2034771449 hasConceptScore W2034771449C141071460 @default.
• W2034771449 hasConceptScore W2034771449C19527891 @default.
• W2034771449 hasConceptScore W2034771449C2776235491 @default.
• W2034771449 hasConceptScore W2034771449C2776845205 @default.
• W2034771449 hasConceptScore W2034771449C2777416452 @default.
• W2034771449 hasConceptScore W2034771449C2778648096 @default.
• W2034771449 hasConceptScore W2034771449C2780192828 @default.
• W2034771449 hasConceptScore W2034771449C2781074409 @default.
• W2034771449 hasConceptScore W2034771449C2989005 @default.
• W2034771449 hasConceptScore W2034771449C3017588741 @default.
• W2034771449 hasConceptScore W2034771449C509974204 @default.
• W2034771449 hasConceptScore W2034771449C71924100 @default.
• W2034771449 hasConceptScore W2034771449C77411442 @default.
• W2034771449 hasIssue "5" @default.
• W2034771449 hasLocation W20347714491 @default.
• W2034771449 hasLocation W20347714492 @default.
• W2034771449 hasOpenAccess W2034771449 @default.
• W2034771449 hasPrimaryLocation W20347714491 @default.
• W2034771449 hasRelatedWork W2012940595 @default.

• next